Genmab AS (GMAB) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $29.24
• Market Cap: $18.05B
• P/E Ratio: 19.02
• EPS: $1.54
• 52-Week High: $35.43
• 52-Week Low: $17.23

Market Sentiment

Genmab AS currently has a Neutral sentiment score of 0.09.

About Genmab AS

Genmab AS is a prominent biotechnology company based in Copenhagen, Denmark, renowned for its innovative development of specialized antibody therapeutics aimed at treating cancer and other critical illnesses. The company boasts a strong pipeline supported by its proprietary technologies and strategic collaborations, driving advancements in next-generation therapies. With a steadfast commitment to improving patient outcomes through targeted immunotherapies, Genmab is well-positioned to capital...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Genmab AS and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does GMAB pay dividends?

Genmab AS (GMAB) does not currently pay a regular dividend.

What is GMAB's P/E ratio?

Genmab AS has a price-to-earnings (P/E) ratio of 19.02.

What is GMAB's market cap?

Genmab AS (GMAB) has a market capitalization of $18.05B with a current stock price of $29.24.